Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06116526 · ClinicalTrials.gov registry record · Phase 4
Dupilumab De-escalation in Pediatric Atopic Dermatitis
A Phase 4 study of Atopic Dermatitis, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06116526: Recruiting Phase 4 study of Atopic Dermatitis, sponsored by Johns Hopkins University.
NCT06116526 is a Phase 4 study of Atopic Dermatitis that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 30 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06116526, a Phase 4 study of Atopic Dermatitis, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot investigator-blinded, randomized clinical trial to assess the feasibility of dupilumab treatment discontinuation or dose-reduction in children aged 1-17 years who have achieved sustained atopic dermatitis (AD) control on dupilumab.
Primary Outcome
Successful de-escalation is defined as maintaining a reduced dose (i.e., less frequent administration) of dupilumab after initial de-escalation on week 0. Patients who require re-escalating the dose of dupilumab to standard dosing or adding other systemic treatments for their AD will be regarded as treatment failure.
Conditions Studied
Interventions
- DRUG Dupilumab - Standard Dose
- DRUG Dupilumab - Discontinuation
- DRUG Dupilumab - Dose Reduction
Study Locations (1)
Maryland
- Johns Hopkins Univerisity - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 4 |
What NCT06116526 shows while recruiting
NCT06116526 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 3 interventions - of which Dupilumab - Standard Dose is the first listed.
NCT06116526 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT06116526 about?
NCT06116526 is a clinical study titled "Dupilumab De-escalation in Pediatric Atopic Dermatitis". This is a pilot investigator-blinded, randomized clinical trial to assess the feasibility of dupilumab treatment discontinuation or dose-reduction in children aged 1-17 years who have achieved sustained atopic dermatitis (AD) control on dupilumab.
What is the current status of trial NCT06116526?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2024-04-01. Estimated completion is 2027-04-30.
What conditions does trial NCT06116526 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT06116526?
The interventions under investigation include: Dupilumab - Standard Dose (DRUG), Dupilumab - Discontinuation (DRUG), Dupilumab - Dose Reduction (DRUG).
Who is sponsoring clinical trial NCT06116526?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06116526 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06116526's enrollment target sits among peer trials
30 120th of 150 higher than 25 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
RECRUITING · Phase 4
-
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
RECRUITING · Phase 4
-
Molecular Signatures of Cutaneous Dupilumab Response
RECRUITING · Phase 4
-
Ethnic Differences in Mechanisms of Action of Dupilumab
RECRUITING · Phase 4
-
Dupixent and Narrowband UVB for Atopic Dermatitis
RECRUITING · Phase 4
-
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI